Table 1.
Classic external beam radiotherapy.
| Author | Year | Histology |
Exclusive/
Adjuvant |
N. lesions N. patients |
N. Fractions | Dose/Fraction | Total Dose |
Local control 2 years |
Local control 5 years | 5-year Disease-Free Survival |
|---|---|---|---|---|---|---|---|---|---|---|
| Silva et al. (13) | 2000 | BCC (201) SCC (122) Basosquamous (11) |
Exclusive | 334 lesions 313 patients |
1 5 10 20–30 |
17.5–20 Gy 7 Gy 4.2–4.5 Gy <3 Gy |
17.5–20 Gy 35 Gy 42.5–45Gy 50–65 Gy |
87% | 79% | |
| Veness et al. (14) | 2005 | SCC with metastatic lymph nodes | Adjuvant | 167 lesions 167 patients | 25–37 | 2 Gy |
50–74 Gy |
73% vs. 54% (surgery alone). | ||
| Caccialanza et al. (12) | 2013 | BCC SCC |
Exclusive | 986 lesions 905 patients |
92–96% | |||||
| Porceddu et al. (15) | 2018 | SCC (310) | Adjuvant Adjuvant +chemotherapy | 157 patients 153 patients |
30–33 | 2 Gy | 60–66 Gy |
88% 89% |
83% 87% |
67% 73% |
| Voruganti et al. (16) | 2021 | BCC (14) SCC (77) Others (15) |
Exclusive | 112 lesions 106 patients |
4–6 | 5–8 | 25Gy 32–35 Gy 40 Gy 45 Gy 48–50 Gy |
67% | ||
| De Felice et al. (17) | 2021 | SCC (23) | Exclusive | 23 lesions 18 patients |
8 | 7–8 | 56–64 Gy | 23.5% (2–year) |